Bioventus Inc. (BVS) Quality Score
Valuation remains strong (avg 95/100), but business quality is pulling the composite down (avg 35/100).
Broad-market heuristics · Not a buy/sell signal
Valuation and growth
Valuation
Growth
Under 20x, reasonable relative to earnings
Under 20x cash flow, well covered
2–5% CAGR, growing but slowly
Above 10% CAGR, strong compounder
Business Quality & Capital Allocation
Heavy dilution above 5%
Expanded 3+pp, strong improvement
Net debt/FCF of 2.5x, high leverage
8–10%, clearing the bar
Bioventus (BVS) quality: score, margins and returns
Bioventus (BVS) scores 66/100 on Intrinsiqq's quality score (a solid business), a weighted blend of 8 metrics each scored 0 to 100, on 10.0% operating margins and 9.3% ROIC. Every metric is computed from SEC filings; this is analysis, not investment advice.
Frequently asked
Is Bioventus (BVS) a high-quality business?+
Bioventus scores 66 out of 100 on Intrinsiqq's quality score, a weighted blend of 8 metrics each scored 0 to 100, which rates it a solid business on these measures. Recent figures include a 10.0% operating margin and a 9.3% return on invested capital. Quality and price are separate questions: even a great business can be a poor investment if you overpay, so read this score alongside the valuation. The metric-by-metric breakdown is on this scorecard.
What does Bioventus's quality score measure?+
Intrinsiqq's quality score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, change in share count, and balance-sheet strength, each computed from BVS's SEC filings rather than opinion or sentiment. A higher score means a more durable, capital-efficient business; it is not a buy or sell signal. Open each metric on this page to see exactly where Bioventus scores well and where it falls behind.
What is Bioventus's return on invested capital (ROIC)?+
Bioventus earns about 9.3% on its invested capital, which is modest. ROIC measures how much profit a company generates per dollar put to work; sustained ROIC above its cost of capital is one of the clearest signs of a real competitive moat. Compare it to BVS's margins and growth on this scorecard to judge durability.
How profitable is Bioventus?+
Bioventus runs an operating margin of about 10.0% and a net margin of about 9.4%. Revenue has grown at roughly 12.1% a year recently. High, stable margins usually point to pricing power and operating discipline. Margins are most telling next to growth and returns on capital, all of which feed this quality score. This is analysis from SEC filings, not investment advice.
SourceQuality score computed from the 10-Q filed 5 Aug 2026, covering the period ending 27 Jun 2026, as reported to the SEC. Data last refreshed 18 Sept 2026. How this is calculated.
Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically. Checks use broad-market heuristics, so sector norms may differ, and the valuation checks are more cyclical than the quality checks.
Related stocks: Surgical & Medical Instruments & Apparatus
Spot a number that looks wrong?
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.